Inhibrx Biosciences Inc. has announced progress updates on its ongoing clinical programs. The company is currently conducting a randomized Phase 2/3 clinical trial of INBRX-106 in combination with Keytruda® (pembrolizumab) as a first-line treatment for patients with unresectable or metastatic head and neck squamous cell carcinoma (HNSCC). As of the latest update, 46 out of a planned 60 patients have been enrolled in the Phase 2 portion, with full enrollment expected in the first quarter of 2026. The primary endpoint is overall response rate, with secondary endpoints including duration of response, progression free survival, and safety. Additionally, Inhibrx has completed enrollment of a Phase 1/2 trial involving 34 patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC), also in combination with Keytruda. Primary endpoints for this cohort are objective response rate, disease control rate, duration of response, and safety. Currently, the datasets for both HNSCC and NSCLC lack sufficient maturity for interpretation or conclusions regarding the viability of the INBRX-106 program. The company anticipates that data mature enough to inform efficacy and clinical benefit will be available in the second half of 2026. No final results have been presented at this time.